MedPath

Dazodalibep

Generic Name
Dazodalibep

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: Sep 29, 2025

Dazodalibep: A Comprehensive Analysis of a Novel CD40 Ligand Antagonist for Autoimmune Disease

Executive Summary

Dazodalibep is an investigational, second-generation therapeutic agent representing a significant potential advancement in the treatment of autoimmune diseases, most notably Sjögren's Syndrome. Classified as a non-antibody fusion protein, Dazodalibep functions as a highly specific antagonist of the CD40 ligand (CD40L), a critical component of the immune system's co-stimulatory axis. Its molecular architecture was strategically engineered to circumvent the severe thromboembolic toxicities that halted the development of first-generation anti-CD40L monoclonal antibodies, a feat achieved by eliminating the problematic Fc region. The drug's mechanism of action is centered on the blockade of the CD40/CD40L interaction, thereby disrupting the pathological communication between T cells, B cells, and other antigen-presenting cells that drives autoimmunity.

The clinical development program, now under the stewardship of Amgen following its acquisition of Horizon Therapeutics, is anchored by compelling results from a robust Phase 2, randomized, placebo-controlled, crossover trial (NCT04129164) in Sjögren's Syndrome. This study uniquely targeted two distinct patient populations: one with moderate-to-severe systemic disease activity and another with a high burden of patient-reported symptoms. Dazodalibep met its primary endpoints with high statistical significance in both groups, demonstrating a profound ability to reduce objective measures of systemic disease activity (measured by the ESSDAI score) and to provide clinically meaningful improvements in the debilitating symptoms of dryness, fatigue, and pain (measured by the ESSPRI score). The drug was found to be generally safe and well-tolerated, with no evidence of the thromboembolic events that plagued its predecessors.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/12/24
Phase 3
Recruiting
2024/02/07
Phase 3
Recruiting
2023/10/27
Phase 3
Active, not recruiting
2022/01/21
Phase 2
Recruiting
2019/11/22
Phase 2
Withdrawn
2019/11/15
Phase 2
Completed
2019/10/16
Phase 2
Completed
2019/08/06
Phase 2
Completed
2016/05/23
Phase 1
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.